- Total Issue Size: Rs 3,042.62 crore
- Price Band: ₹522 to ₹549
- IPO Closes: December 13, 2024
- Listing Date: December 18, 2024 (Tentative)
- Strong Financial Growth: PAT up 729% in FY23.
- Global Presence: Servicing major pharmaceutical clients across key regions.
Sai Life Sciences is raising Rs 3,042.62 crore through its IPO, which includes a fresh issue of Rs 950 crore and an offer for sale (OFS) of Rs 2,092.62 crore. The IPO, open for subscription since December 11, 2024, will close today, December 13, 2024.
The price band for the IPO is set between ₹522 to ₹549 per share, with a minimum lot size of 27 shares. The retail investor’s minimum investment is ₹14,823, while high-net-worth individuals (HNIs) must invest at least 14 lots.
The IPO allotment is expected on December 16, 2024, and the shares will tentatively list on the BSE and NSE on December 18, 2024.
Sai Life Sciences IPO Details
| Particulars | Details |
|---|---|
| IPO Dates | December 11 to December 13, 2024 |
| Listing Date | December 18, 2024 (Tentative) |
| Issue Size | Rs 3,042.62 crore |
| Fresh Issue | Rs 950 crore |
| Offer for Sale (OFS) | Rs 2,092.62 crore |
| Price Band | ₹522 to ₹549 per share |
| Lot Size | 27 shares |
| Issue Type | Book Built Issue |
| Listing Exchange | BSE, NSE |
| Registrar | KFin Technologies Ltd |
| Lead Managers | Kotak Mahindra Capital, Jefferies, Morgan Stanley, IIFL Securities |
Sai Life Sciences IPO Timeline (Tentative)
| Event | Date |
|---|---|
| IPO Open Date | December 11, 2024 |
| IPO Close Date | December 13, 2024 |
| Basis of Allotment | December 16, 2024 |
| Initiation of Refunds | December 17, 2024 |
| Credit of Shares to Demat | December 17, 2024 |
| Listing Date | December 18, 2024 |
| UPI Mandate Confirmation | December 13, 2024 (5 PM) |
Get priority access to the latest updates, tips, and special announcements. Join our WhatsApp channel to always stay ahead.
Sai Life Sciences IPO Lot Size
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 27 | 14,823 |
| Retail (Max) | 13 | 351 | 192,699 |
| S-HNI (Min) | 14 | 378 | 207,522 |
| B-HNI (Min) | 68 | 1,836 | 1,007,964 |
Sai Life Sciences IPO Reservation
| Investor Category | Shares Offered | Allocation (%) |
|---|---|---|
| QIB | 1,10,84,225 | 20% |
| NII (HNI) | 83,13,168 | 15% |
| – sNII (<₹10L) | 27,71,056 | 5% |
| – bNII (>₹10L) | 55,42,113 | 10% |
| Retail Investors | 1,93,97,392 | 35% |
| Anchor Investors | 1,66,26,336 | 30% |
| Total Shares | 5,54,21,121 | 100% |
Sai Life Sciences: Company Overview
Incorporated in 1999, Sai Life Sciences provides contract research and development (CRDMO) services to global pharmaceutical companies. The company serves over 280 clients across the US, UK, Europe, and Japan, including 18 of the top 25 pharma companies by revenue.
- Core Services:
- Contract Development and Manufacturing (CDMO)
- Integrated Discovery Services (CRO) for biology, chemistry, and pharmacokinetics
- Staff Strength (as of Sept 30, 2024):
- Scientific Staff: 2,353 (includes 302 PhDs)
- Total Employees: 3,135
Sai Life Sciences Financials (Restated Consolidated)
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 2,476.78 | 2,275.14 | 2,186.65 | 2,164.23 |
| Revenue | 693.35 | 1,494.27 | 1,245.11 | 897.74 |
| Profit After Tax | 28.01 | 82.81 | 9.99 | 6.23 |
| Net Worth | 1,044.75 | 974.34 | 887.29 | 877.76 |
| Borrowings | 764.49 | 710.16 | 699.23 | 751.32 |
All values in ₹ crore.
Competitive Strengths
- Integrated CRDMO Services: Offers complete discovery, development, and manufacturing solutions.
- CRO Expertise: Strong capabilities in biology, chemistry, and pharmacokinetics.
- Global Client Base: Serving top pharmaceutical companies worldwide.
- Qualified Team: Highly skilled workforce with advanced degrees.
Objects of the IPO
The net proceeds from the IPO will be used for:
- General corporate purposes
- Repayment/prepayment of borrowings
Disclaimer: The information provided in this article is for informational purposes only and does not constitute financial advice or an endorsement of any IPO or investment opportunity. While we strive to ensure the accuracy of the details shared, the content is based on publicly available information, research, and reports from credible sources. Readers are advised to verify the details independently and consult with a financial advisor before making any investment decisions.Stay informed and exercise caution while making financial decisions.
Create Your Wealth with Paytm Money
